Xintela AB publishes Annual Report 2025
Xintela AB (publ) announces that the company’s annual report for 2025 is published on the company’s website www.xintela.se and is attached to this announcement. Link to the annual report: https://www.xintela.se/en/report-archive Contacts Xintela AB (publ)Evy Lundgren-Åkerlund, CEOTel: +46 46 275 65 00Email: evy@xintela.seMedicon Village223 81 Lund, Swedenwww.xintela.se About Xintela Xintela (XINT) is a publicly-traded clinical-stage biopharma company, […]
Xintela AB Year-end Report 2025
Summary of the year-end reportThe “Company” or “Xintela” refers to Xintela AB (publ), corporate registration number 556780-3480. The GroupForth quarter 2025Income amounted to TSEK 415 (1,090).Loss before tax totalled TSEK 17,343 (loss: 11,712).Loss per share was SEK 0.02 (loss: 0.02). Full year 2025Income amounted to TSEK 2,282 (4,215).Loss before tax totalled TSEK 50,158 (loss: 41,534).Loss per share […]
Xintela AB Interim Report January – September 2025
Summary of the interim reportThe “Company” or “Xintela” refers to Xintela AB (publ), corporate registration number 556780-3480. The GroupThird quarter 2025Income amounted to TSEK 855 (2,822).Loss before tax totalled TSEK 10,035 (loss: 8,049).Loss per share was SEK 0.01 (loss: 0.01). First nine month of 2025Income amounted to TSEK 1,867 (3,125).Loss before tax totalled TSEK 32,816 (loss: […]
Xintela announces subsidiary Targinta collaboration with MSK Therapeutics Accelerator
Xintela (XINT) announces that Xintela’s oncology subsidiary, Targinta AB, has today initiated a collaboration with Memorial Sloan Kettering Cancer Center’s (MSK’s) Therapeutics Accelerator in New York, USA, for development of its integrin α10β1 antibody therapeutic in patients with aggressive sarcoma. Under the collaboration, Targinta will produce antibodies targeting integrin α10β1 and complete preclinical development work […]
Xintela’s stem cell product XSTEM shows safety and sustained positive efficacy results two years after treatment in knee osteoarthritis clinical study
The final analysis including the 24-month evaluation of Xintela’s (XINT) clinical study on XSTEM for knee osteoarthritis has now been completed. The results show continued safety, reduction of knee pain, improved joint function, and improvements in bone and cartilage structure. This confirms a sustained treatment effect in knee osteoarthritis and supports a disease-modifying effect of […]
Xintela AB Interim Report January – June 2025
Summary of the interim reportThe “Company” or “Xintela” refers to Xintela AB (publ), corporate registration number 556780-3480. The GroupSecond quarter 2025Income amounted to TSEK 872 (4).Loss before tax totalled TSEK 12,119 (loss: 10,400).Loss per share was SEK 0.02 (loss: 0.02). First half year 2025Income amounted to TSEK 1,012 (303).Loss before tax totalled TSEK 22,780 (loss: 21,773).Loss […]
Xintela strengthens management team with Peter Ekolind as COO & VP Commercial Manufacturing
Xintela announces the appointment of Peter Ekolind as Chief Operating Officer (COO) and Vice President Commercial Manufacturing. Peter started his position on August 18, 2025.With this recruitment, Xintela reinforces its focus on the company’s GMP manufacturing facility, a strategic asset for the commercial production of cell therapy products as well as for the supply of […]
Xintela AB changes Certified Adviser to Tapper Partners AB
Xintela AB announces today that the company is changing its Certified Adviser to Tapper Partners AB. Xintela AB has entered into an agreement with Tapper Partners AB regarding the role as Certified Adviser. Tapper Partners AB will assume the role of Certified Adviser on August 15, 2025. Until then, DNB Carnegie Investment Bank AB will […]
Xintela AB Interim Report January – March 2025
Summary of the interim reportThe “Company” or “Xintela” refers to Xintela AB (publ), corporate registration number 556780-3480. The GroupFirst quarter 2025Income amounted to TSEK 140 (299).Loss before tax totalled TSEK 10,427 (loss: 10,997).Loss per share was SEK 0.02 (loss: 0.02). The Parent companyFirst quarter 2025Income amounted to TSEK 140 (299).Loss before tax totalled TSEK 8,574 (loss: 9,688). Significant […]
Xintela AB publishes Annual Report 2024
Xintela AB (publ) announces that the company’s annual report for 2024 is published on the company’s website www.xintela.se and is attached to this announcement. Link to the annual report: https://www.xintela.se/en/report-archive Contacts Xintela AB (publ)Evy Lundgren-Åkerlund, CEOTel: +46 46 275 65 00Email: evy@xintela.seMedicon Village223 81 Lund, Swedenwww.xintela.se About Xintela Xintela develops medical products in stem cell […]
